Studying Biomarkers in Samples From Younger Patients With Kidney Cancer

Clear Cell Renal Cell Carcinoma Clinical Trial

Official title:

Focal Adhesion Kinase Expression in Pediatric Renal Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01642095
• Other study ID #: AREN12B8
• Secondary ID: NCI-2012-01987CD
• Status: Withdrawn
• Start date: August 22, 2012

Study information

• Verified date: October 2017
• Source: Children's Oncology Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This laboratory study is looking into biomarkers in samples from younger patients with kidney cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors find better ways to treat cancer.

Description:

PRIMARY OBJECTIVES:

I. To determine whether focal adhesion kinase (FAK) is expressed and if FAK is phosphorylated in pediatric renal tumors.

OUTLINE:

Archived tumor tissue samples are analyzed for FAK expression by immunohistochemistry (IHC). IHC staining is compared in normal renal tissue, Wilms tumor (routine and anaplastic), malignant rhabdoid tumor of the kidney, clear cell sarcoma of the kidney, and mesoblastic nephroma.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. primary completion date: September 1, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Formalin-fixed, paraffin-embedded tissue samples from patients diagnosed with the following renal tumors:

• Anaplastic Wilms tumor

• Malignant rhabdoid tumor of the kidney

• Clear cell sarcoma of the kidney

• Mesoblastic nephroma

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Childhood Kidney Neoplasm
• Clear Cell Renal Cell Carcinoma
• Congenital Mesoblastic Nephroma
• Kidney Neoplasms
• Rhabdoid Tumor
• Rhabdoid Tumor of the Kidney

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations

Country	Name	City	State
United States	Childrens Oncology Group	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Children's Oncology Group	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	FAK expression in pediatric renal tumors		Baseline